Key Highlights
- PHR shares fell 7.74% pre-market to $10.96, reversing a 0.25% gain in the prior session.
- Fiscal second-quarter Revenue reached $129.5 million, up 10% year over year and modestly ahead of estimates.
- Adjusted Earnings Per Share came in well short of consensus expectations for the quarter.
- Adjusted EBITDA rose to $32.9 million, a 25% margin, up from the prior-year period.
- The company reaffirmed its full-year revenue outlook of $510 million to $520 million.
Bottom-Line Shortfall Overshadows Revenue Growth
Phreesia (NYSE:PHR) shares declined in pre-market trading after the company's fiscal second-quarter results showed adjusted earnings per share falling significantly short of Wall Street expectations, even as revenue grew double digits and came in ahead of estimates. The mismatch between top-line strength and bottom-line disappointment drove the stock's pre-market pullback.
Phreesia provides a cloud-based software and payment platform that helps medical practices and health systems manage patient intake, registration, scheduling, and payment processing across the United States and Canada.
Sequential Revenue Dip Tied to Seasonal Factors
Revenue was down modestly on a sequential basis, which the company attributed to seasonal patterns in payment processing activity rather than a change in underlying demand. Adjusted EBITDA nonetheless improved year over year, and the company reported positive Net Income and free Cash Flow for a consecutive quarter, alongside continued Debt reduction.
Phreesia carries a market Capitalization of roughly $734 million following the pre-market decline. The stock trades at a trailing price-to-earnings ratio near 70.6, reflecting its still-developing profitability profile even as it reported positive net income for a fifth consecutive quarter.
Guidance Reaffirmed Despite Near-Term Pressure
Management maintained its full-year revenue outlook, along with its adjusted EBITDA range, and pointed to growth drivers including new Business wins in its financing solutions and continued expansion of its provider network. The company also highlighted early results from artificial intelligence integration across its platform tools aimed at improving prescription volumes and patient engagement.
Profitability Trajectory Now the Focus for Investors
With revenue growth and reaffirmed guidance intact, the pre-market decline suggests investors are focused on the pace of Margin expansion and earnings consistency rather than top-line momentum alone. The next Quarterly Report will be closely watched for signs of stabilized bottom-line performance.






Please wait processing your request...